Close Menu
Thermo Fisher Scientific: Marc Casper, Jim Manzi, Thomas Lynch
Thermo Fisher Scientific's board of directors has elected Marc Casper its chairman, effective immediately. Casper, who is the company's president and CEO, succeeds Jim Manzi, who will continue to serve as a director on Thermo Fisher's board. Manzi has been a director at the company since May 2000 and was chairman of the board for 15 years. Also, Thomas Lynch has been elected as lead independent director, effective immediately.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.